Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028

The Company plans to purchase up to $200 million worth of shares concurrently with, or shortly after, the pricing of the offering SAN DIEGO, Aug. 15, 2022 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”), a leader in converting IV biologics to…

Click here to view original post